Unknown

Dataset Information

Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients.


ABSTRACT:

Background and objectives

A dose-finding study was undertaken to investigate the efficacy of PA21, a novel polynuclear iron(III)-oxyhydroxide phosphate binder.

Design, setting, participants, & measurements

In a randomized, active-controlled, multicenter, open-label study at 50 clinical sites in Europe and the United States, hemodialysis patients were randomized to PA21 at dosages of 1.25, 5.0, 7.5, 10.0, or 12.5 g/d or sevelamer-HCl 4.8 g/d for 6 weeks. The primary efficacy endpoint was the change in serum phosphorus concentration from baseline.

Results

There were 154 participants who were randomized and received the study drug. All groups except PA21 1.25 g/d showed a significant decrease in serum phosphorus. Mean decreases in serum phosphorus in PA21 10 g/d and 12.5

SUBMITTER: Wuthrich RP 

PROVIDER: S-EPMC3562865 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature